 |
 |
|
|
|
| Lenalidomide |
 |
| Lenalidomide |
 |
| [191732-72-6] |
 |
Use: Lenalidomide (initially known as CC-5013 and marketed as Revlimid by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes.
The exact mechanism of the immunomodulatory drugs (i.e. thalidomide, CC-4047/Actimid and lenalidomide) is now known. Apart from interfering with the immune systhem, they are also thought to act on angiogenesis.
Lenalidomide and bortezomib are considered therapeutic breakthroughs in myeloma, which generally carries a poor prognosis.
|
 |
CAS No.: [ 191732-72-6]
Appearance: Off-white to pale yellow powder.
Solubility: Slightly soluble in methanol and acetonitrile.
Total Impurities: max1.0%
Heavy Metals: max20PPM
Water(by K.F): max4.0%
Residue On Ignition: max0.1%
Assay: min99%.
|
|
|
|
|
|
